NewAmsterdam Pharma (NAMS) Change in Accured Expenses (2023 - 2026)

NewAmsterdam Pharma has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$10.3 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$10.3 million, down 108.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.9 million (down 55.3% YoY), and the FY2025 annual result was $2.4 million, up 45.2% from the prior year.
• Change in Accured Expenses came in at -$10.3 million for Q1 2026 at NewAmsterdam Pharma, down from $5.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $9.3 million in Q3 2023 to a low of -$10.3 million in Q1 2026.
• The 4-year median for Change in Accured Expenses is $402000.0 (2024), against an average of -$55846.2.
• Peak annual rise in Change in Accured Expenses reached 431.0% in 2025, while the deepest fall reached 258.65% in 2025.
• NewAmsterdam Pharma's Change in Accured Expenses stood at -$5.8 million in 2023, then surged by 141.3% to $2.4 million in 2024, then surged by 122.39% to $5.3 million in 2025, then tumbled by 294.03% to -$10.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$10.3 million (Q1 2026), $5.3 million (Q4 2025), and $638000.0 (Q3 2025), per Business Quant data.